A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 1/4/2012

Posted by | 10:07pm on Wednesday, January 4, 2012

:
Welcome to the first #socpharm tweetchat of 2012! How is everyone tonight?

:
As always, we’ll assume the views expressed on #socpharm tonight are your personal views & do not reflect that of your employer.

:
Whatta ya think? Social Health Networks to Change Medicine In 2012. http://t.co/NwoJkfDl (via @) #HITsm #mdchat #socpharm #in

:
hello everyone, haven’t been in a #socpharm for a bit, but glad to be back! #socpharm

:
Hello #socpharm ers, welcome to 2011!

:
Hey Eileen!! :) #socpharm

:
@: Also… they reflect opinions at this time, and do not constitute legal opinions :) #socpharm

:
#socpharm I mean goodbye 2011, hello 2012…. oops!

:
@ Interesting question – we should talk about it during #socpharm tonight after we talk recent FDA guidance.

:
@ @: @: Welcome everyone! #socpharm

:
weird, tweetchat reset, made me rehash and login … #socpharm

:
So, whats our discussion about today? #socpharm

:
Has everyone read about latest FDA guidance? http://t.co/LV26PZTF & http://t.co/0eefcHZZ #socpharm

:
Hello @: Welcome to the first #socpharm tweetchat of 2012! How is everyone tonight?

:
@: Yup.. just happened to me. I logged out and logged back on. #socpharm

:
T1: Is it accurate to call recent FDA guidance social media guidelines? #socpharm

:
Happy New Year all! Looking forward to hearing more thought about FDA guidelines #socpharm

:
@: Yup. #socpharm

:
I like this part, like a space-time continuum thing… RT @: : @: Also… they reflect opinions at this time… #socpharm

:
yes RT @: : Has everyone read about latest FDA guidance? http://t.co/6tzJdpjp & http://t.co/hD5AgmAn #socpharm

:
@: FDA doesnt expect to “distinguish” b/w SM and trad media (4 good reason). It applies to both SM & Trad. But more SM #socpharm

:
I think so RT @: : T1: Is it accurate to call recent FDA guidance social media guidelines? #socpharm

:
I like @ take: not direct guidance but you can read between the numerated lines. #socpharm

:
Either way: Here are the topics FDA announced it would release. This is the first of 6. #socpharm

:
Do you think guidance said anything new about social media? #socpharm

:
Here are the topics they want to provide Guidances on: http://t.co/0NB3I8eg #socpharm

:
@: Yes… what do you do if asked off-label questions (We can thank IMS v. Sorrell/Citizens Petition/Par) #socpharm

:
having more tweetchat troubles – switching browsers… #socpharm

:
Tx for reminding us. RT @: Here are the topics they want to provide Guidances on: http://t.co/PhZW2xGg #socpharm

:
Can we apply this guidance to on-label unsolicited requests? #socpharm

:
#socpharm I guess it’s one of several pieces of guidance, certainly a lot left to cover but Rome wasn’t built in a day!

:
ok, i think i am back #socpharm

:
@: In what context? #socpharm

:
Joining already lively the #socpharm chat. Hi all.

:
@: Welcome back #socpharm

:
the summary and the ‘so-what’ from @ #fdasm #socpharm #hcmktg http://t.co/uNcqzc6c

:
@: IMO people were expecting a lot out of a single guidance. As you put it, its a brick in a wall. The wall will get blt ltr #socpharm

:
one of the issues w guidance w/i the lines of guidance is that it took so long 2 get here, and we r not in an #sm steady state. #socpharm

:
@: Trying to cause trouble. Is it working? or do I need to shout louder/go stand in the corner 4 being 2 loud? #socpharm

:
@ If woman asks in public forum, is it ok to take my RX Brand if I’m pregnant? & label said no. Could co same way? #socpharm

:
@: Think of this as a “bolus”. You need 5/7.5 “1/2 lives”/guidances to reach steady state ;) #socpharm

:
True! RT @: : #socpharm I guess it’s one of several pieces of guidance, certainly a lot left to cover but Rome wasn’t built in a day!

:
@: Depends on details, but could direct to specific portion of risk info on label. Must be careful not to prescribe. #socpharm

:
expectation blt ovr time bcause of FDA inaction, no? RT @: : @: IMO ppl were expectng alot out of a single guidance.. #socpharm

:
@‘s post is apt. The application to SOPs is the key for pharma. It’ll have to be cross-functional though. #socpharm

:
#socpharm @: You make a good point, it doesn’t look like that topic is on the FDA’s list to be covered either.

:
@: FDA announced its goals. We just expected them to exceed the goals :) #socpharm

:
@: I’m interested to learn more about “sm steady state”… #socpharm

:
@: Shout louder! :) #socpharm

:
@: The delay was potentially expected due to the lawsuits/cit. pet/Par #socpharm

:
@: In my case, it was just some pharma humor. Sorry. (Referring to steady state of drugs: 5.5-7 1/2 lives) #socpharm

:
@ Can you hear me now?!! (TM Verizon) #socpharm

:
w/i a fast moving target @: @: Think of as a “bolus”. u need 5/7.5 “1/2 lives”/guidances 2 reach steady state ;) #socpharm

:
Frieda Hernandez here from Siren joining late and will try to catch up #socpharm

:
@ So in sm listening when c unsolicited rx on-label question we could say “contact med/sci to learn more” &link 2 label? #socpharm

:
point is that #SM will never be in a steady state. RT @: @: I’m interested 2learn more abt “sm steady state”… #socpharm

:
@ Sorry, got the bolus reference at least! #socpharm

:
@: I would have to be convinced otherwise. Its on label, provides adequate risk info (may need simplified version) #socpharm

:
@: how many patients can really understand label? #socpharm

:
@: Exactly: So, may need simplified version #socpharm

:
@: Hey Friedah :) #socpharm

:
If FDA says it’s in interest of public health 4 pharma to help to correct off-label requests, is it same for on-label requests? #socpharm

:
@: : @: re steady state, bolus, still gr8 exampl, reactive to readings past, not predictive of future. #socpharm

:
@: FDA would be hard pressed to prove why it would apply to one not another. #socpharm

:
It’s important to make the distinction between an SM guidance and the off-label comm guidance that was issued. #socpharm

:
@: Again, the big fear is going into prescribing. #socpharm

:
Anyone have any insight in how FDA decides whether or not to do a press release on issuance of guidance? They did this quietly #socpharm

:
where? RT @: : Its important 2 make distinction between an SM guidance & the off-label comm guidance that was issued. #socpharm

:
I’m w/ u! MT @: It’s important to make distinction between an SM guidance & the off-label comm guidance that was issued. #socpharm

:
@: They dont expect to ever announce a “SM Guidance” per se. Will likely be “read b/w lines” #socpharm

:
#socpharm @: FDA snuck this in with the hopes we wouldn’t all see it and start clamoring for additional guidance ;-)

:
is burden on FDA or party? RT @: : @: FDA would be hard pressed to prove why it would apply to one not another. #socpharm

:
@: I think their press dept. decides that. #socpharm

:
@ Right, need to keep it non-promotional. None of us sales/marketers involved. #socpharm

:
@: @ FDA trying to be platform agnostic. #socpharm

:
@: I dont know if thats established. I would need to look at the lawsuits to be sure. #socpharm

:
LOL RT @: : #socpharm @: FDA snuck this in with the hopes we wouldn’t all see & start clamoring for additional guidance ;-)

:
on FB, how would user know if marketer or other? RT @: : @ …None of us sales/marketers involved. #socpharm

:
@: Yup. Need to have the right controls in place. #socpharm

:
@: user may not. But FDA/HHS/OIG/DOJ/US Attorneys may look. #socpharm

:
@: Hey.. I am both promotion/ non promotional :) #socpharm

:
@: #socpharm The off-l;abel guidance is applicable beyond SM. Was not meant as an SM guidance, but for first time offers clues.

:
but isnt potential trouble convo initiated by user? RT @: : @: Yup. Need to have the right controls in place. #socpharm

:
@: Sure: But controls are initiated by Industry #socpharm

:
@: True, but if u want to follow guidance it should be medical/science rep who transparently states relationship to co. #socpharm

:
Has to be. RT @: : @: @ FDA trying to be platform agnostic. #socpharm

:
@: FDA typically ambiguious-leads to tighter interpretation by pharma, IMHO. Not holding my breath.Wise interpretation best #socpharm

:
@: Hey there, Darshon. Having some Tweetdeck issues so on 10 minute delay :-( #socpharm

:
but SM would seem like place where easiest to get into ‘trouble’ RT @: : @: …guidance is applicable beyond SM… #socpharm

:
RT @: @: True, but if u want to flw guidance it should be medical/science rep who transparently states relation #socpharm

:
@: #socpharm Perhaps, but it’s an understated guidance, so the understated release isn’t surprising, right? :)

:
@: Tweet chat had similar issues. #socpharm

:
yes, bt difficulty changes based on platform (ie 140 chars) RT @: : @: Sure: But controls are initiated by Industry #socpharm

:
FYI – Hootsuite is working fine tonight. #socpharm

:
@: Yes, but true 4 many issues. FDA unlikely to be platform specific. #socpharm

:
@: I always have a tough time following via hootsuite. Will try. #socpharm

:
@: Absolutely & really the FDA wants pharma to take it to “non-public” conversation. #socpharm

:
understood of course RT @: : @: Yes, but true 4 many issues. FDA unlikely to be platform specific. #socpharm

:
Tweetdeck issues. Sorry #socpharm folks, I’m about 10 minutes out of the loop. :(

:
LOL! MT @: @: #socpharm it’s an understated guidance, so the understated release isn’t surprising, right? :)

:
All late comers please line up in the back. Seating has been on a first come first serve basis ;) Welcome all!! :) #socpharm

:
Anything else anybody wants to say about FDA guidance? #socpharm

:
glad i’m not alone in being alone RT @: : @: Hey Darshon. Having some Tweetdeck issues so on 10 minute delay :-( #socpharm

:
@: Seems like a lot more potential for non-FDA approved behavior in non-public sphere and lack of accountability #socpharm

:
@: Curious: What were people expecting? #socpharm

:
I guess – understated guidance better than no guidance @ all? RT @: : Anything else anybody wants 2say abt FDA guidance? #socpharm

:
@: hahah!! :) #socpharm

:
That biggest take away 4 me RT @: : really the FDA wants pharma to take it to “non-public” convo #socpharm

:
@: I guess it is FDA’s way of saying if I don’t see what you’re saying I don’t have to judge whether it is right/wrong #socpharm

:
Agreed RT @: : SM would seem where easiest for ‘trouble’ RT @: : @: …guidance is applicable beyond SM… #socpharm

:
That’s biggest take away 4 me RT @: : really the FDA wants pharma to take it to “non-public” convo #socpharm

:
But this non-public discourse will be documented @: @: potential 4 non-FDA approved behavior lack accountability #socpharm

:
@: I disagree. I think its saying that dont spread unapproved indications publicly. #socpharm

:
@: FDA retains right to see what they are saying. #socpharm

:
@: Exactly. You must have med/promo SOPs in place to ensure correct info going out. #socpharm

:
Agreed RT @: : @: I disagree. I think its saying that dont spread unapproved indications publicly. #socpharm

:
Maybe I’m too literal but I was surprised by how excited everyone was & immediate tagging it “SM guidelines” #socpharm

:
I agree RT @: : @: I disagree. I think its saying that dont spread unapproved indications publicly. #socpharm

:
great post/graphic by @ – you’ll never guide a social media strategy from regulators #socpharm

:
@: May be necessary 4 safety/efficacy in private. #socpharm

:
@: Very true. #socpharm

:
@: I would: Expectations need to be tempered. Expecting clarity will only entrench the existing inertia. #socpharm

:
@: Well, it explicitly discusses SM. Also, it was one of the guidances “we” tagged as SM. Hence the excitement. #socpharm

:
start with this and work together as an industry – we need more sharing/consensus building – cautiously optimistic about 2012 #socpharm

:
Personally, i was surprised that the guidance came out this soon. I thought there would be a delay for a little longer at least. #socpharm

:
You say inertia, I say caution. #socpharm

:
for another POV would point to this piece by Peter Pitts http://t.co/rLtwoP9W #socpharm

:
Right. RT @: Maybe I’m too literal but was surprised by how excited everyone was & immediate tagging it “SM guidelines” #socpharm

:
@: like after election? #socpharm

:
@: No, after lawsuits #socpharm

:
In a public discourse chances of off-label discussion might be higher RT @: necessary 4 safety/efficacy in private #socpharm

:
RT @: RT @: The FDA gets it right on social media marketing http://t.co/qepUG2eY #hcsm #socpharm #mHealth #epha

:
Hi @: ! Mark Bard is tweeting on behalf of Digital Health Coalition http://t.co/E9P8BJuv & will b moderating next Wed #socpharm

:
@: Exactly why they need to be controlled/ SOPs put in place. #socpharm

:
we need more examples of using technology – and social – to optimize public health #socpharm

:
ah. RT @: : @: No, after lawsuits #socpharm

:
outcomes will require an investment – in an era of cuts – tough but necessary #socpharm

:
@: Several pending (can off-label be controlled)/ can FDA guide using guidances primarily #socpharm

:
totally agree RT @: : we need more examples of using technology – and social – to optimize public health #socpharm

:
thanks @: – looking forward to next week #socpharm

:
just another part o/t challenge RT @: : outcomes will require an investment – in an era of cuts – tough but necessary #socpharm

:
But it IS inertia. The SOPs and infrastructure mostly exist. Adapting to changing regulations is what pharma excels at, no? #socpharm

:
In last few minutes here’s a non-pharma topic:Man sued 4 keeping company #Twitter followers http://t.co/gYKHzb7D Bound to happen? #socpharm

:
also believe industry and trade groups need cooperation to move conversation forward and provide practical solutions #socpharm

:
@: Depends on what he was hired for. #socpharm

:
RT @: n a public discourse chances of off-label discussn might b ^ RT @: necessary 4 safety/efficacy in prvit #socpharm

:
@: #Twitter #socpharm That case was followed closely by a company going after an employee’s #in acct. Inevitable? Sure.

:
RT @: : Man sued 4 keeping company #Twitter followers http://t.co/GCobA5kA Bound to happen? #socpharm

:
@ You could easily see how it could happen with Twitter & FB, ownership of accounts gets murky. #socpharm

:
and of course educating the people making decisions who have no idea what twitter is – the people running the show in many cases #socpharm

:
Agreed RT @: : also believe industry & trade groups nd cooperation 2move convo 4ward & provide practical solutions #socpharm

:
@: Eg. If I hire someone to maintain my twitter account. I expect it back at the end. #socpharm

:
@ Hadn’t heard about that other case. Do u have link? I find it fascinating. #socpharm

:
@: Conversely, if I was not expected to tweet. Much easier to argue that its not company property. #socpharm

:
was interesting read RT @: Man sued 4 keeping company #Twitter followers http://t.co/evZ2RUnl Bound 2happen? #socpharm

:
@: Yea, I saw that too. The linkedin argument is much more tortured than the twitter argument. #socpharm

:
seems most companies are learning to link the corporate brand to those with a gift for twitter – expect that to increase #socpharm

:
@: @: We had the same thought #socpharm

:
Thanks everyone for another lively discussion. As noted, Mark Bard aka @: will be guest moderating next Wed. #socpharm

:
Hey… gonna head off soon. Please come by 4 our next #rxcom chat next monday at 9pm EST. Discuss: Sunshine Act Guidance. #socpharm

:
THanks @: for hosting and fellow #socpharm ers for a great chat!

:
where’s this end up – murky? RT @: : Conversely, if I ws not expected 2tweet. Much easier 2argue its not company property. #socpharm

:
which point r u referring 2? RT @: @: @: We had the same thought #socpharm

:
Let’s hope. RT @: : seems most cos learning 2 link corp brand 2 those with gift for twitter – expect that to increase #socpharm

:
Absolutely, thx Eileen and all! RT @: : THanks @: for hosting and fellow #socpharm ers for a great chat! #socpharm

:
@: Murky 4 now. But purpose will often be likely to control. #socpharm

:
will consult twitter grammar guide for appropriate shorthand next week – thanks #socpharm

:
Thank you! RT @: : Tx everyone for another lively discussion. Mark Bard @: will be moderating next Wed. #socpharm

:
@: @: I’ve seen more and more dual tweets, same perason, company and personal id’s. who owns these follows? #socpharm

:
Thank you all!!! #socpharm

:
:) RT @: : will consult twitter grammar guide for appropriate shorthand next week – thanks #socpharm

:
MT @: Please come by 4 our next #rxcom chat next monday at 9pm EST. Discuss: Sunshine Act Guidance. #socpharm #hcsm #hcmktg

:
@: Thank you Eileen. You think you may be able to make it? #socpharm

:
@ I’m at an HBA event that ends at 9 pm, but I’ll check out #rxcom chat when I get home. It’s on my calendar :) #socpharm

:
Great to participate in my first #socpharm. Thanks everyone.

:
Well, I hope to see you there!! #socpharm

:
@ Thanks for sharing your insights. #socpharm

:
@: The one to which we replied. Re draft guidance vs actual “SM guidelines” #socpharm

:
@ We missed you at the chat :) #socpharm

:
@: Thanks, Eileen. Likewise! #socpharm

:
Sorry, tweetchat dysfunctionl 2nite @ @: The 1 2which we replied. Re draft guidance vs actual “SM guidelines” #socpharm

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

One Pingback/Trackback

    11 January 2012 at 12:01am
    Just posted much-delayed transcript ...
  • Eileen O'Brien
  • Pingback: Eileen O'Brien()

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com